Difference between revisions of "Peripheral T-cell lymphoma"
m (→References) |
|||
Line 3: | Line 3: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
+ | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
+ | |- | ||
+ | |<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div> | ||
+ | <div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div> | ||
+ | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Untreated= | =Untreated= | ||
− | ==CHOEP-14 -> upfront autologous SCT== | + | ==CHOEP-14 -> upfront autologous SCT {{#subobject:e84b92|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
CHOEP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone | CHOEP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone | ||
− | ===Regimen, d'Amore et al. 2012 (NLG-T-01)=== | + | ===Regimen, d'Amore et al. 2012 (NLG-T-01) {{#subobject:b15c3a|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 35: | Line 44: | ||
# d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9. Epub 2012 Jul 30. [http://jco.ascopubs.org/content/30/25/3093.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22851556 PubMed] | # d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9. Epub 2012 Jul 30. [http://jco.ascopubs.org/content/30/25/3093.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22851556 PubMed] | ||
− | ==CHOP== | + | ==CHOP {{#subobject:38ee4a|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | ||
Line 42: | Line 55: | ||
Structured Concept: [http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary==NCI%20Thesaurus&version==12.09d&code==C9549&key==1801231401&b==1&n==null C9549] (NCI-T), [http://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary==NCI%20MetaThesaurus&code==C0055598 C0055598] (NCI-MT/UMLS) | Structured Concept: [http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary==NCI%20Thesaurus&version==12.09d&code==C9549&key==1801231401&b==1&n==null C9549] (NCI-T), [http://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary==NCI%20MetaThesaurus&code==C0055598 C0055598] (NCI-MT/UMLS) | ||
− | ===Regimen, Simon et al. 2010 (GOELAMS LTP95)=== | + | ===Regimen, Simon et al. 2010 (GOELAMS LTP95) {{#subobject:f500e0|Variant=1}}=== |
<span | <span | ||
style="background:#00CD00; | style="background:#00CD00; | ||
Line 60: | Line 73: | ||
====Radiation therapy for initial bulky disease==== | ====Radiation therapy for initial bulky disease==== | ||
− | ''"Initial bulky disease": patients with "diameter | + | ''"Initial bulky disease": patients with "diameter =5 cm"'' |
*Radiation therapy, 40 Gy at 1.8 Gy/day to the involved field | *Radiation therapy, 40 Gy at 1.8 Gy/day to the involved field | ||
Line 66: | Line 79: | ||
# Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010 Oct;151(2):159-66. Epub 2010 Aug 25. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08329.x/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20738307 PubMed] | # Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010 Oct;151(2):159-66. Epub 2010 Aug 25. [http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08329.x/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20738307 PubMed] | ||
− | ==CHOP -> upfront autologous SCT== | + | ==CHOP -> upfront autologous SCT {{#subobject:3db6eb|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | ||
− | ===Regimen, Reimer et al. 2004, 2009=== | + | ===Regimen, Reimer et al. 2004, 2009 {{#subobject:8d8890|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 93: | Line 110: | ||
# '''Meta-analysis:''' Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;2011:623924. Epub 2011 Jun 16. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197255/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22084700 PubMed] | # '''Meta-analysis:''' Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;2011:623924. Epub 2011 Jun 16. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197255/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22084700 PubMed] | ||
− | ==DD-CHOP== | + | ==DD-CHOP {{#subobject:b07d3a|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
DD-CHOP: '''<u>D</u>'''enileukin, '''<u>D</u>'''iftitox, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | DD-CHOP: '''<u>D</u>'''enileukin, '''<u>D</u>'''iftitox, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin, '''<u>O</u>'''ncovin, '''<u>P</u>'''rednisone | ||
− | ===Regimen, Foss et al. 2013 (CONCEPT)=== | + | ===Regimen, Foss et al. 2013 (CONCEPT) {{#subobject:897f8d|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 125: | Line 146: | ||
=Relapsed/refractory= | =Relapsed/refractory= | ||
− | ==Belinostat (Beleodaq)== | + | ==Belinostat (Beleodaq) {{#subobject:2a8653|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, O'Connor et al. 2013 (BELIEF); Pohlman et al. 2014=== | + | ===Regimen, O'Connor et al. 2013 (BELIEF); Pohlman et al. 2014 {{#subobject:682543|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 144: | Line 169: | ||
# Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print] [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13222/full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25404094 PubMed] | # Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print] [http://onlinelibrary.wiley.com/doi/10.1111/bjh.13222/full link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25404094 PubMed] | ||
− | ==Bendamustine (Treanda)== | + | ==Bendamustine (Treanda) {{#subobject:47c984|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, Demaj et al. 2013 (BENTLY)=== | + | ===Regimen, Demaj et al. 2013 (BENTLY) {{#subobject:1e407d|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 161: | Line 190: | ||
# Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. [http://jco.ascopubs.org/content/31/1/104.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23109692 PubMed] | # Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. [http://jco.ascopubs.org/content/31/1/104.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23109692 PubMed] | ||
− | ==Brentuximab vedotin (Adcetris)== | + | ==Brentuximab vedotin (Adcetris) {{#subobject:b71ea8|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, Horwitz et al. 2014=== | + | ===Regimen, Horwitz et al. 2014 {{#subobject:e3235|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 179: | Line 212: | ||
# Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. Epub 2014 Mar 20. [http://www.ejcancer.com/article/S0959-8049%2813%2900363-8/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24652992 PubMed] | # Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. Epub 2014 Mar 20. [http://www.ejcancer.com/article/S0959-8049%2813%2900363-8/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24652992 PubMed] | ||
− | ==DHAP== | + | ==DHAP {{#subobject:f4e87b|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
DHAP: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (cytarabine), '''<u>P</u>'''latinol (cisplatin) | DHAP: '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (cytarabine), '''<u>P</u>'''latinol (cisplatin) | ||
− | ===Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)=== | + | ===Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12) {{#subobject:f5009d|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 200: | Line 237: | ||
# Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed] | # Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed] | ||
− | ==GDP== | + | ==GDP {{#subobject:7ceb1c|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
GDP: '''<u>G</u>'''emcitabine, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol | GDP: '''<u>G</u>'''emcitabine, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol | ||
− | ===Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)=== | + | ===Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12) {{#subobject:67023b|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 221: | Line 262: | ||
# Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed] | # Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed] | ||
− | ==Lenalidomide (Revlimid)== | + | ==Lenalidomide (Revlimid) {{#subobject:372121|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, Morschhauser et al. 2013 (EXPECT)=== | + | ===Regimen, Morschhauser et al. 2013 (EXPECT) {{#subobject:b6993e|Variant=1}}=== |
<span | <span | ||
style="background:#EEEE00; | style="background:#EEEE00; | ||
Line 238: | Line 283: | ||
# Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. Epub 2013 May 31. [http://www.ejcancer.com/article/S0959-8049%2813%2900363-8/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23731832 PubMed] | # Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. Epub 2013 May 31. [http://www.ejcancer.com/article/S0959-8049%2813%2900363-8/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23731832 PubMed] | ||
− | ==Pralatrexate (Folotyn)== | + | ==Pralatrexate (Folotyn) {{#subobject:c2c35b|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
===Example orders=== | ===Example orders=== | ||
*[[Example orders for Pralatrexate (Folotyn) in peripheral T-cell lymphoma]] | *[[Example orders for Pralatrexate (Folotyn) in peripheral T-cell lymphoma]] | ||
− | ===Regimen, O'Connor et al. 2011 (PROPEL)=== | + | ===Regimen, O'Connor et al. 2011 (PROPEL) {{#subobject:9606fa|Variant=1}}=== |
<span | <span | ||
Line 257: | Line 306: | ||
*[[Cyanocobalamin (Vitamin B12)]] 1 mg IM once every 8 to 10 weeks | *[[Cyanocobalamin (Vitamin B12)]] 1 mg IM once every 8 to 10 weeks | ||
*[[Folic acid (Folate)]] 1 to 1.25 mg PO once per day | *[[Folic acid (Folate)]] 1 to 1.25 mg PO once per day | ||
− | **"Elevated methylmalonic acid (>200 nmol/L) and/or homocysteine (>10 | + | **"Elevated methylmalonic acid (>200 nmol/L) and/or homocysteine (>10 µmol/L) at screening required initiation of [[Folic acid (Folate)]] and [[Cyanocobalamin (Vitamin B12)]] = 10 days before the first dose of [[Pralatrexate (Folotyn)]]." |
'''7-week cycles, given until progression of disease, unacceptable toxicity, or patient/physician preference''' | '''7-week cycles, given until progression of disease, unacceptable toxicity, or patient/physician preference''' | ||
Line 265: | Line 314: | ||
# O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. [http://jco.ascopubs.org/content/29/9/1182.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21245435 PubMed] | # O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. [http://jco.ascopubs.org/content/29/9/1182.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21245435 PubMed] | ||
− | ==Romidepsin (Istodax)== | + | ==Romidepsin (Istodax) {{#subobject:510429|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#toc|back to top]] | ||
+ | |} | ||
− | ===Regimen, Coiffier et al. 2012=== | + | ===Regimen, Coiffier et al. 2012 {{#subobject:fd7901|Variant=1}}=== |
<span | <span |
Revision as of 03:04, 9 February 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
30 regimens on this page
37 variants on this page
|
Untreated
CHOEP-14 -> upfront autologous SCT
back to top |
CHOEP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Etoposide, Prednisone
Regimen, d'Amore et al. 2012 (NLG-T-01)
Phase II
Etoposide is omitted for patients older than 60 years of age.
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 3
- Prednisone (Sterapred) 50 mg PO BID on days 1 to 5
14-day cycle x 6 cycles
If patients in PR or CR after three cycles, stem cells are mobilized off of cycles 5 and 6, followed by:
References
- d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9. Epub 2012 Jul 30. link to original article contains verified protocol PubMed
CHOP
back to top |
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Synonyms: CHOP-21, ACOP, CAVP, COPA, VACP, VCAP
Structured Concept: C9549 (NCI-T), C0055598 (NCI-MT/UMLS)
Regimen, Simon et al. 2010 (GOELAMS LTP95)
Phase III
The evaluation arm, VIP-rABVD, was not superior and is not included here.
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose per cycle: 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg/m2 PO once per day on days 1 to 5
21-day cycles x 8 cycles
Radiation therapy for initial bulky disease
"Initial bulky disease": patients with "diameter =5 cm"
- Radiation therapy, 40 Gy at 1.8 Gy/day to the involved field
References
- Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010 Oct;151(2):159-66. Epub 2010 Aug 25. link to original article contains verified protocol PubMed
CHOP -> upfront autologous SCT
back to top |
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Regimen, Reimer et al. 2004, 2009
Phase II
This study reports using CHOP but doesn't specify the doses; below is a fairly standard CHOP regimen:
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 1
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
21-day cycle x 4 to 6 cycles
If CR obtained after 4 cycles or at least a PR after 6 cycles, patients were mobilized with G-CSF 4 to 6 weeks after, and then proceeded to receive either DexaBEAM or ESHAP induction followed by autologous stem cell transplant. Details are not available with regards to the conditioning regimens.
References
- Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V, Weissinger F, Nerl C, Schmitz N, Müller-Hermelink HK, Wilhelm M. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5(4):304-11. PubMed
- Update: Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, Engert A, Einsele H, Müller-Hermelink HK, Wilhelm M. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106-13. Epub 2008 Nov 24. link to original article PubMed
- Meta-analysis: Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;2011:623924. Epub 2011 Jun 16. link to original article PubMed
DD-CHOP
back to top |
DD-CHOP: Denileukin, Diftitox, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Regimen, Foss et al. 2013 (CONCEPT)
Phase II
- Denileukin diftitox (Ontak) 18 mcg/kg IV over 60 minutes once per day on days 1 & 2
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV once on day 3
- Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 3
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once on day 3
- Prednisone (Sterapred) 100 mg PO once per day on days 3 to 7
Supportive medications:
- Dexamethasone (Decadron) 4 to 8 mg IV/PO prior to Denileukin diftitox (Ontak)
- Acetaminophen (Tylenol) 650 mg PO prior to Denileukin diftitox (Ontak)
- Diphenhydramine (Benadryl) 25 mg IV prior to Denileukin diftitox (Ontak)
- Normal saline 250 to 500 cc before and after each Denileukin diftitox (Ontak) infusion
- Antiemetics "per institutional standard"
- G-CSF support beginning on day 4
21-day cycles x 6 to 8 cycles
References
- Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013 Jul;54(7):1373-9. Epub 2013 Jan 29. link to original article contains verified protocol PubMed
Relapsed/refractory
Belinostat (Beleodaq)
back to top |
Regimen, O'Connor et al. 2013 (BELIEF); Pohlman et al. 2014
Phase II
- Belinostat (Beleodaq) 1000 mg/m2 IV over 30 minutes once per day on days 1 to 5
3-week cycles
References
- Abstract: Owen A. O'Connor, Tamás Masszi, Kerry J. Savage, Lauren C. Pinter-Brown, Francine M. Foss, Leslie Popplewell, Amanda F. Cashen, Jeanette Doorduijn, Shanta Chawla, Poul Knoblauch, Pier Luigi Zinzani, Peter Brown, Georg Hess, Achiel Van Hoof, Steven M. Horwitz, Andrei R. Shustov. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. J Clin Oncol 31, 2013 (suppl; abstr 8507) link to abstract
- Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print] link to original article contains protocol PubMed
Bendamustine (Treanda)
back to top |
Regimen, Demaj et al. 2013 (BENTLY)
Phase II
- Bendamustine (Treanda) 120 mg/m2 IV once per day over 30 to 60 minutes on days 1 & 2
3-week cycles x 6 cycles
References
- Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Béné MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. Epub 2012 Oct 29. link to original article contains verified protocol PubMed
Brentuximab vedotin (Adcetris)
back to top |
Regimen, Horwitz et al. 2014
Phase II
- Brentuximab vedotin (Adcetris) 1.8 mg/kg IV on day 1
3-week cycle until progression or unacceptable toxicity
References
- Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. Epub 2014 Mar 20. link to original article contains verified protocol PubMed
DHAP
back to top |
DHAP: Dexamethasone, High-dose Ara-C (cytarabine), Platinol (cisplatin)
Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)
Phase III, <20 in this arm
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
- Cytarabine (Cytosar) 2000 mg/m2 IV over 3 hours Q12H x 2 doses on day 2 (total of 2 doses)
- Cisplatin (Platinol) 100 mg/m2 IV continuous infusion over 24 hours on day 1
21-day cycles x up to 3 cycles
References
- Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. link to original article contains verified protocol PubMed
GDP
back to top |
GDP: Gemcitabine, Dexamethasone, Platinol
Regimen #1, Crump et al. 2014 (NCIC-CTG LY.12)
Phase III, <20 in this arm
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
- Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
21-day cycles x up to 3 cycles
References
- Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. link to original article contains verified protocol PubMed
Lenalidomide (Revlimid)
back to top |
Regimen, Morschhauser et al. 2013 (EXPECT)
Phase II
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
28-day cycles, up to 2 years
References
- Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J Cancer. 2013 Sep;49(13):2869-76. Epub 2013 May 31. link to original article contains protocol PubMed
Pralatrexate (Folotyn)
back to top |
Example orders
Regimen, O'Connor et al. 2011 (PROPEL)
Phase II
- Pralatrexate (Folotyn) 30 mg/m2 IV push over 3 to 5 minutes once per day on days 1, 8, 15, 22, 29, 36
Supportive medications:
- Cyanocobalamin (Vitamin B12) 1 mg IM once every 8 to 10 weeks
- Folic acid (Folate) 1 to 1.25 mg PO once per day
- "Elevated methylmalonic acid (>200 nmol/L) and/or homocysteine (>10 µmol/L) at screening required initiation of Folic acid (Folate) and Cyanocobalamin (Vitamin B12) = 10 days before the first dose of Pralatrexate (Folotyn)."
7-week cycles, given until progression of disease, unacceptable toxicity, or patient/physician preference
References
- O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9. link to original article contains verified protocol PubMed
Romidepsin (Istodax)
back to top |
Regimen, Coiffier et al. 2012
Phase II
- Romidepsin (Istodax) 14 mg/m2 IV over 4 hours once per day on days 1, 8, 15
28-day cycles, up to 6 cycles, with optional extension of treatment for patients with stable disease or response
References
- Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. Epub 2012 Jan 23. link to original article contains verified protocol PubMed
- Update: Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23;7(1):11. link to original article PubMed